Academic Journal

Dual-Spherical Multifunctional Nanomotors for Intravesical Bladder Cancer Therapy.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος: Dual-Spherical Multifunctional Nanomotors for Intravesical Bladder Cancer Therapy.
Συγγραφείς: Chen Y; Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.; The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China., Zheng B; Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China., Liu Z; Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China., Wang H; Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China., Xu L; School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, People's Republic of China., Qin X; Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China., Sun L; Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China., Li H; Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China., Xu W; Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China., Mou Y; Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China., Wang C; Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China., Hua X; Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China., Zhou X; Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China., Liu D; Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China., Zuo W; Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China., Zhang C; Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China., Zhang P; Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China., Zhang D; Urology & Nephrology Center, Department of Urology, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, People's Republic of China.; The Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
Πηγή: International journal of nanomedicine [Int J Nanomedicine] 2025 Dec 06; Vol. 20, pp. 14613-14628. Date of Electronic Publication: 2025 Dec 06 (Print Publication: 2025).
Τύπος έκδοσης: Journal Article
Γλώσσα: English
Στοιχεία περιοδικού: Publisher: DOVE Medical Press Country of Publication: New Zealand NLM ID: 101263847 Publication Model: eCollection Cited Medium: Internet ISSN: 1178-2013 (Electronic) Linking ISSN: 11769114 NLM ISO Abbreviation: Int J Nanomedicine Subsets: MEDLINE
Imprint Name(s): Original Publication: Auckland : DOVE Medical Press
Ιατρικοί όροι (MeSH): Urinary Bladder Neoplasms*/drug therapy , Urinary Bladder Neoplasms*/pathology , Deoxycytidine*/analogs & derivatives , Deoxycytidine*/administration & dosage , Deoxycytidine*/pharmacokinetics , Deoxycytidine*/pharmacology , Deoxycytidine*/chemistry , Nanoparticles*/chemistry, Urease/chemistry ; Urease/metabolism ; Glucose Oxidase/chemistry ; Gemcitabine ; Humans ; Animals ; Cell Line, Tumor ; Administration, Intravesical ; Mice ; Female
Περίληψη: Background: Conventional intravesical chemotherapy for bladder cancer has shown limited clinical efficacy. To overcome this challenge, self-propelled nanomotors, including urease-modified nanomotors, have been developed. These nanomotors enhance drug diffusion in urine, offering advantages over traditional drugs and passive nanoparticles. However, a key issue remains: the inability to maintain long-term urease activity.
Methods: Nanozymes, glucose oxidase, and urease are synthesized into a three-enzyme nanomotors via biomineralization, serving as a power source. Cell membrane nanoparticles loaded with gemcitabine were combined with three-enzyme nanomotors to form dual-spherical nanomotors. TEM, DLS, and analyses of urease/glucose oxidase activity and nanomotor trajectories confirmed successful nanomotor fabrication. These nanomotors can regulate tumor cell glucose metabolism and release gemcitabine upon cellular entry, achieving a dual anticancer effect.
Results: Nanomotors synthesized through biomineralization methods exhibit the ability to retain long-term activity. After intravesical instillation, urease-containing nanomotors decomposed urea to produce carbon dioxide and ammonia, propelling rapid nanoparticle movement for deep bladder wall penetration. The homing ability of the tumor membrane-coated nanoparticles enhanced nanomotor accumulation in tumor cells. Subsequently, the nanomotors release Gox and gemcitabine, which significantly inhibit tumor progression.
Conclusion: This innovative strategy utilizes gemcitabine - loaded nanomotors to penetrate the mucus layer and target tumors, inducing cell death for the treatment of bladder cancer.
(© 2025 Chen et al.)
Competing Interests: The authors report no conflicts of interest in this work.
References: Cells. 2021 Jul 06;10(7):. (PMID: 34359874)
Angew Chem Int Ed Engl. 2015 Jan 26;54(5):1414-44. (PMID: 25504117)
Micromachines (Basel). 2023 Apr 29;14(5):. (PMID: 37241607)
Int J Nanomedicine. 2019 Feb 18;14:1213-1227. (PMID: 30863055)
CA Cancer J Clin. 2021 May;71(3):209-249. (PMID: 33538338)
Nanoscale. 2021 Oct 28;13(41):17386-17395. (PMID: 34611685)
Adv Mater. 2020 Jul;32(28):e1908435. (PMID: 32459030)
Eur Urol. 2022 Jan;81(1):75-94. (PMID: 34511303)
ACS Nano. 2019 Dec 24;13(12):13985-13994. (PMID: 31833366)
Talanta. 2021 Apr 1;225:122071. (PMID: 33592789)
Adv Sci (Weinh). 2020 Aug 07;7(18):2001388. (PMID: 32999845)
Nat Nanotechnol. 2019 Aug;14(8):799-809. (PMID: 31263194)
Int J Nanomedicine. 2020 Feb 05;15:675-704. (PMID: 32103936)
BJU Int. 2011 Aug;108(3):455-9. (PMID: 21156021)
J Nanobiotechnology. 2023 Oct 24;21(1):388. (PMID: 37875896)
J Virol. 2015 Jan;89(1):844-56. (PMID: 25355889)
Adv Mater. 2019 May;31(21):e1808325. (PMID: 30907460)
Analyst. 2012 Feb 7;137(3):595-600. (PMID: 22179722)
BMC Cancer. 2017 Nov 23;17(1):790. (PMID: 29169339)
ACS Nano. 2020 Jun 23;14(6):6683-6692. (PMID: 32491832)
J Am Chem Soc. 2004 Oct 20;126(41):13424-31. (PMID: 15479099)
Anticancer Res. 2019 Mar;39(3):1105-1118. (PMID: 30842139)
J Contam Hydrol. 2018 Jan;208:61-67. (PMID: 29269033)
Acc Chem Res. 2017 Jan 17;50(1):2-11. (PMID: 27809479)
Nano Lett. 2019 Jul 10;19(7):4334-4342. (PMID: 31179709)
Cancers (Basel). 2021 Jan 03;13(1):. (PMID: 33401585)
Sci Rep. 2021 May 13;11(1):10181. (PMID: 33986399)
Nanoscale. 2022 Jan 20;14(3):898-909. (PMID: 34985483)
J Colloid Interface Sci. 2023 Aug;643:373-384. (PMID: 37080044)
J Control Release. 2022 Jul;347:632-648. (PMID: 35618186)
Chem Commun (Camb). 2005 Jan 28;(4):441-3. (PMID: 15654363)
BJU Int. 2021 Aug;128(2):225-235. (PMID: 33450116)
Adv Mater. 2017 Feb;29(6):. (PMID: 27891683)
ACS Nano. 2014 Sep 23;8(9):8794-801. (PMID: 24911046)
Nat Rev Dis Primers. 2023 Jan 12;9(1):1. (PMID: 36635355)
J Nanobiotechnology. 2025 May 17;23(1):355. (PMID: 40380217)
Contributed Indexing: Keywords: bladder cancer; intravesical therapy; nanomotor
Substance Nomenclature: EC 3.5.1.5 (Urease)
0 (Gemcitabine)
0W860991D6 (Deoxycytidine)
EC 1.1.3.4 (Glucose Oxidase)
Entry Date(s): Date Created: 20251212 Date Completed: 20251212 Latest Revision: 20251214
Update Code: 20260130
PubMed Central ID: PMC12691648
DOI: 10.2147/IJN.S552418
PMID: 41383278
Βάση Δεδομένων: MEDLINE
Περιγραφή
ISSN:1178-2013
DOI:10.2147/IJN.S552418